☆ 4.6 Article

Beyond PD-L1-Identification of Further Potential Therapeutic Targets in Oral Cancer

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

Glenn J. Hanna et al.

Summary: This study investigated the use of dual immune-checkpoint inhibition in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN) before and after surgery. The results showed a promising response rate and suggests further evaluation of this strategy.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

Clinical outcome and prognostic factors in recurrent oral squamous cell carcinoma after primary surgical treatment: a retrospective study

Sven Zittel et al.

Summary: Survival outcomes for radiotherapy-naive patients with recurrent oral squamous cell carcinoma were evaluated, with surgical therapy showing significantly better disease-free survival and overall survival compared to other treatment modalities. Presence of regional metastases and short disease-free interval between primary and recurrent cancer were significant predictors for adverse outcomes.

CLINICAL ORAL INVESTIGATIONS (2022)

添加到收藏夹

Article Otorhinolaryngology

Neck dissection and trans oral robotic surgery for oropharyngeal squamous cell carcinoma

Giuseppe Meccariello et al.

Summary: This study aimed to determine whether Selective Neck Dissection (SND) is a safe procedure for patients with lymph node metastases. The results showed no significant differences in overall survival, disease-free survival, and regional recurrence free survival between SND and Modified Radical Neck Dissection (MRND) groups. Advanced stage was found to impact the 5-year overall survival and disease-free survival. Therefore, the indication for SND should be carefully discussed in a TORS framework.

AURIS NASUS LARYNX (2022)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood

Falk Wehrhan et al.

Summary: The study found a significant increase in PD1 receptor expression in oral squamous cell carcinoma tissue, which was positively correlated with its ligands PD-L1 and PD-L2, suggesting that the interaction of PD-L1/PD-L2-PD1 may be a major mediator of local immunosuppression in OSCC, requiring advanced treatment protocols.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model

Kun-Hung Lee et al.

Summary: The study describes the discovery of orally active and selective CSF1R inhibitors, demonstrating their potent anti-tumor effects through in vivo experiments. By utilizing molecular docking and structural studies, the researchers were able to enhance the potency of the inhibitors and alter the tumor microenvironment to increase the M1/M2 ratio.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Platelet-expressed immune checkpoint regulator GITRL in breast cancer

Yanjun Zhou et al.

Summary: Studies have shown that platelets from cancer patients have higher levels of GITRL, which is specifically regulated during tumor progression by clinical parameters. This indicates that platelets modulate the GITR/GITRL immune checkpoint in the context of malignant disease and provide a rationale for further research into using this axis for immunotherapeutic intervention in cancer patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Oncology

Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors

Antian Gao et al.

Summary: This review discusses the advantages of anti-PD-1/PD-L1 therapy for oral squamous cell carcinoma (OSCC) patients, and identifies three aspects currently available for predicting treatment efficacy.

INVESTIGATIONAL NEW DRUGS (2021)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma

Songtao Zhang et al.

Summary: The study showed that the expression of CMTM6 and PD-1/PD-L1 was significantly higher in OSCC tissues compared to paracancerous tissues. PD-L1 expression was associated with clinical stage and lymph node metastasis in OSCC. qRT-PCR results confirmed the relationship between mRNA and protein expression.

ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2021)

添加到收藏夹

Review Oncology

Prognostic Significance of CD4+and CD8+Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

Daniele Borsetto et al.

Summary: This study provides evidence for the prognostic significance of CD8+ and CD4+ TILs in HNSCC, with variations in tumor subsite needing further investigation. TILs may serve as predictive biomarkers for risk stratifying patients and further research is needed in the application of immune-checkpoint inhibitors.

CANCERS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia

Jutta Ries et al.

Summary: Increased levels of PD-1 and PD-L1 are associated with malignant transformation in oral leukoplakia (OLP) and may serve as a promising prognostic indicator to determine the risk of malignant progression of OLP.

BIOMEDICINES (2021)

添加到收藏夹

Article Oncology

Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano et al.

Summary: The study aimed to evaluate the safety and efficacy of Sabatolimab and spartalizumab in patients with advanced solid tumors. The results showed that the combination of Sabatolimab plus spartalizumab was well tolerated and showed signs of antitumor activity, with the recommended dose for Sabatolimab being 800 mg Q4W, with or without 400 mg spartalizumab Q4W.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study

Marc Oliva et al.

Summary: The SNOW study demonstrates that sitravatinib plus nivolumab is safe and results in deep clinical and pathological responses in oral cavity carcinomas. Multi-omic biomarker analyses dissect the differential molecular effects of sitravatinib versus the sitravatinib-nivolumab and reveal patients with distinct tumor biology behavior.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Review Oncology

Next generation of immune checkpoint inhibitors and beyond

Julian A. Marin-Acevedo et al.

Summary: The immune system plays a crucial role in defending against cancer, but tumor cells can evade immune recognition. Immunotherapy enhances host immune response to combat tumors.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical Insights Into Novel Immune Checkpoint Inhibitors

Jii Bum Lee et al.

Summary: The success of immune checkpoint inhibitors has revolutionized solid tumor treatment, but challenges remain with lack of response and immune related adverse events. Targeting other immune checkpoints associated with tumor microenvironment offers promising options to overcome limitations of ICIs.

FRONTIERS IN PHARMACOLOGY (2021)

添加到收藏夹

Review Oncology

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Navid Sobhani et al.

Summary: Immunotherapies have shown promise in cancer treatment but face challenges. Understanding the molecular mechanisms of immune checkpoint inhibitors and the role of regulatory T cells is crucial for improving cancer therapies.

CANCERS (2021)

添加到收藏夹

Review Oncology

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development

Kenji Hashimoto

Summary: CD137 is a significant immuno-oncology target that provides co-stimulatory signals and activates cytotoxic effects of T cells. Recent advances in targeting technologies have shown promising clinical efficacy signals, but challenges regarding toxicity and potency remain. Further investigation is needed to optimize combination strategies involving CD137 targeting agents for improved clinical safety and efficacy in cancer immunotherapy.

CANCERS (2021)

添加到收藏夹

Review Oncology

Pro-Tumorigenic Macrophage Infiltration in Oral Squamous Cell Carcinoma and Possible Macrophage-Aimed Therapeutic Interventions

Flavia Bruna et al.

Summary: In Oral Squamous Cell Carcinomas (OSCC), M2-like TAMs density is associated with poor survival, and CD206+ M2-TAMs are involved in OSCC progression through epidermal growth factor (EGF) secretion, highlighting CD206's important role as a marker of OSCC progression and therapeutic target.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Evan J. Lipson et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target

Wenjing Qian et al.

Summary: Immune checkpoint therapy has achieved significant efficacy in certain tumor types by blocking inhibitory pathways to release T lymphocytes' function using anti-PD-1/PD-L1 monoclonal antibodies. However, limited efficacy, toxic side effects, and lack of accurate biomarkers pose challenges. Further research is needed to identify more representative predictive and target molecules for improving immune checkpoint therapy outcomes.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review)

Laura Mazilu et al.

Summary: Head and neck cancers, particularly squamous cell carcinoma, are a common and aggressive type of cancer with high mortality rates. The tumor microenvironment, characterized by complex interactions between cellular and non-cellular components, plays a crucial role in patient prognosis and treatment outcome. Understanding immune responses, identifying therapy targets, and utilizing biomarkers are important for optimizing treatment strategies for HNSCC patients.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)

添加到收藏夹

Review Immunology

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Zhouhong Ge et al.

Summary: TIGIT is an inhibitory receptor expressed on multiple types of lymphocytes, and the efficacy of TIGIT blockade in cancer immunotherapy is currently under investigation. While single TIGIT blockade has limited anti-tumor efficacy, co-blockade with the PD-1/PD-L1 pathway leads to tumor rejection.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Oncology

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy

Hirofumi Shibata et al.

Summary: The article discusses the potential of neoadjuvant immunotherapy in enhancing clinical outcomes for HNSCC, highlighting the current mainstay of treatment, limitations of induction chemotherapies, and the success of immunotherapies in recurrent and metastatic cases. It emphasizes the shift in treatment algorithm that neoadjuvant immunotherapy could bring to HNSCC.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer

Clemence Demerle et al.

Summary: Lung cancer is a leading cause of cancer deaths worldwide, and immunotherapies have shown promising results in treatment. However, only 25% of cases show durable responses, highlighting the need for new immunotherapy targets. Among these targets, the BTLA-HVEM couple appears to be a promising candidate for designing new immunotherapies.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prognostic Relevance of CD4+, CD8+ and FOXP3+ TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers

Paloma Lequerica-Fernandez et al.

Summary: This study found that TILs in OSCC patients were associated with PD-L1 expression and CSC markers. CD4(+) and CD8(+) TILs were related to smoking and alcohol habits. High infiltration of CD4(+) and CD8(+) TILs was significantly associated with tumors harboring positive PD-L1 expression.

BIOMEDICINES (2021)

添加到收藏夹

Review Medicine, General & Internal

The association between CD8+tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis

Feng Li et al.

Summary: The study found that high CD8+ TILs were significantly associated with better overall survival, progression-free survival, and objective response rate in cancer patients treated with ICIs. High CD8+ TILs predicted treatment outcomes across different cancers and treatment types.

ECLINICALMEDICINE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

Hyung-Seung Jin et al.

Summary: The review highlights the potential applications of targeting TIGIT, CD226, CD96, and CD112R as new therapeutic targets in cancer immunotherapy. These receptors play crucial roles in regulating immune cell functions through interactions with Nectin and nectin-like molecules. However, further research is needed to fully understand the dynamics and functions of these receptor networks.

BMB REPORTS (2021)

添加到收藏夹

Review Chemistry, Medicinal

Targeting B7-1 in immunotherapy

Rui Chen et al.

MEDICINAL RESEARCH REVIEWS (2020)

添加到收藏夹

Article Pathology

Diminished CD68+ Cancer-Associated Fibroblast Subset Induces Regulatory T-Cell (Treg) Infiltration and Predicts Poor Prognosis of Oral Squamous Cell Carcinoma Patients

Xingxing Zhao et al.

AMERICAN JOURNAL OF PATHOLOGY (2020)

添加到收藏夹

Article Oncology

CD137, an attractive candidate for the immunotherapy of lung cancer

Lingyun Ye et al.

CANCER SCIENCE (2020)

添加到收藏夹

Article Cell Biology

Biological role of GITR/GITRL in attributes and immune responses of macrophage

Zhuo Fu et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Malignant transformation of oral leukoplakia is associated with macrophage polarization

Manuel Weber et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Ravindra Uppaluri et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Tim-3 finds its place in the cancer immunotherapy landscape

Nandini Acharya et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Oncology

Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review

Omar Kujan et al.

CANCERS (2020)

添加到收藏夹

Review Immunology

The Role of GITR/GITRL Interaction in Autoimmune Diseases

Jie Tian et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial

Jonathan D. Schoenfeld et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Oncology

New emerging targets in cancer immunotherapy: the role of GITR

Giulia Buzzatti et al.

ESMO OPEN (2020)

添加到收藏夹

Review Immunology

TIM3 comes of age as an inhibitory receptor

Yochai Wolf et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients

Hong Wang et al.

JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)

添加到收藏夹

Article Oncology

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Ezra E. W. Cohen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Immunology

The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma

Peng Liao et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Oncology

Tumor-infiltrating CD8(+) T-cell density is an independent prognostic marker for oral squamous cell carcinoma

Shota Shimizu et al.

CANCER MEDICINE (2019)

添加到收藏夹

Review Oncology

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

Inaki Etxeberria et al.

ESMO OPEN (2019)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

Oral squamous cell carcinoma of tongue: Histological risk assessment. A pilot study

Blanca del Carmen Miguelanez-Medran et al.

MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

添加到收藏夹

Article Pharmacology & Pharmacy

Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy

Carlo Riccardi et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Interleukin-10 produced by myeloid-derived suppressor cells is critical for the induction of Tregs and attenuation of rheumatoid inflammation in mice

Min-Jung Park et al.

SCIENTIFIC REPORTS (2018)

添加到收藏夹

Article Oncology

PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma

Manuel Weber et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Michael A. Cannarile et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Oncology

Prognostic significance of macrophage polarization in early stage oral squamous cell carcinomas

Manuel Weber et al.

ORAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study

Gregory T. Wolf et al.

ORAL ONCOLOGY (2015)

添加到收藏夹

Article Dentistry, Oral Surgery & Medicine

Small oral squamous cell carcinomas with nodal lymphogenic metastasis show increased infiltration of M2 polarized macrophages - An immunohistochemical analysis

Manuel Weber et al.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2014)

添加到收藏夹

Article Oncology

TNM staging of cancers of the head and neck: Striving for uniformity among diversity

SG Patel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.